Please join CEO Geoffrey Dow as he discusses future plans for testing of ARAKODA® (tafenoquine) for potential use in COVID-19 in light of recent in vitro study results.
Positive Phase II Study Data Suggest ARAKODA® (tafenoquine) Numerically Improved Clinical Recovery in Patients with Mild-Moderate COVID-19 Disease
ARAKODA® (tafenoquine) clinical safety, tolerability confirmed in long-term safety study; results published in Tropical Medicine and Infectious Disease
Data Safety Monitoring Board Recommends Completion of Phase II Study to Evaluate the Efficacy and Safety of ARAKODA® (tafenoquine) for Treatment of Mild-Moderate Covid-19 Disease
60 Degrees Pharmaceuticals Announces Completion of Long-Term Safety of ARAKODA® (tafenoquine) in Healthy Adult Volunteers
60 Degrees Pharmaceuticals Announces Positive Results of Cell Culture Testing of ARAKODA® (tafenoquine) for COVID-19
Arakoda™ (tafenoquine) tablets, first prescription drug approved for malaria prevention by US FDA in over 18 years,
now available in US
60 Degrees Pharmaceuticals (60P) achieves first global product launch milestone
READ MORE
KODATEF® (tafenoquine) approved in Australia; first malaria prevention drug in more than two decades
READ MORE
Military scientists have discovered a new malaria drug that could help eradicate the disease — and it’s hitting shelves soon
READ MORE
U.S. Food and Drug Administration Approves ARAKODA™ (tafenoquine) tablets for oral use
READ MORE
U.S. FDA Advisory Committee votes in favor of Tafenoquine for the prevention of malaria
READ MORE
Cases and 1 Million deaths in the U.S. from COVID-19 infections
Annual deaths from malaria globally
Travelers to endemic regions per annum
Dengue infections per year
1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036